Review of oral cholecystographic agents for the management of hyperthyroidism

Endocrine Practice

Volumn 20, Issue 10, 2014, Pages 1084-1092

  Tyer, Nicole M ^a   Kim, Tiffany Y ^a   Martinez, Dorothy S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIT = amiodarone induced thyroiditis; OCAs = oral cholecystographic agents; TMNG = toxic multinodular goiter

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; IOPANOIC ACID; IOPODATE SODIUM; IOPODIC ACID; POTASSIUM IODIDE; PREDNISONE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE; TYROPANOIC ACID; ANTIARRHYTHMIC AGENT;

ADVERSE OUTCOME; AMIODARONE INDUCED THYROIDITIS; AMIODARONE INDUCED THYROTOXICOSIS; DIARRHEA; DYSURIA; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; NAUSEA; ORAL CHOLANGIOCHOLECYSTOGRAPHY; PREGNANCY; PREOPERATIVE TREATMENT; REVIEW; SUBACUTE THYROIDITIS; THYROID CRISIS; THYROID HORMONE BLOOD LEVEL; THYROIDECTOMY; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN SECRETING ADENOMA; TOXIC GOITER; VOMITING; ADULT; FEMALE; NODULAR GOITER; TUMOR RECURRENCE;

ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; FEMALE; GOITER, NODULAR; HUMANS; HYPERTHYROIDISM; NEOPLASM RECURRENCE, LOCAL; PREGNANCY; THYROIDITIS, SUBACUTE; THYROTOXICOSIS;

EID: 84910117062     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP14024.RA     Document Type: Review

References (73)

1. Hoppe JO, Archer S. Observations on a series of aryl triiodo alkanoic acid derivatives with particular reference to a new cholecystographic medium, telepaque. Am J Roentgenol Radium Ther Nucl Med. 1953;69: 630-637
2. Berk RN, Loeb PM, Goldberger LE, Sokoloff J. Oral Cholecystography with Iopanoic Acid. N Engl J Med. 1974;290: 204-210
3. Fairhurst BJ, Naqvi N. Hyperthyroidism after cholecystography. Br Med J. 1975;3: 630
4. Burgi H, Wimpfheimer C, Burger A, Zaunbauer W, Rosler H, Lemarchand-Beraud T. Changes of circulating thyroxine, triiodothyronine and reverse triiodothyronine after radiographic contrast agents. J Clin Endocrinol Metab. 1976;43: 1203-1210
5. Wu SY, Chopra IJ, Solomon DH, Bennett LR. Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography. J Clin Endocrinol Metab. 1978;46: 691-697
6. Chopra IJ, Solomon DH, Chopra U, Wu SY, Fisher DA, Nakamura Y. Pathways of metabolism of thyroid hormones. Recent Prog Horm Res. 1978;34: 521-567
7. St Germain DL. Dual mechanisms of regulation of type I iodothyronine 5'-deiodinase in the rat kidney, liver, and thyroid gland. Implications for the treatment of hyperthyroidism with radiographic contrast agents. J Clin Invest. 1988;81: 1476-1484
8. Maglinte DD, Torres WE, Laufer I. Oral cholecystography in contemporary gallstone imaging: a review. Radiology. 1991;178: 49-58
9. Shen DC, Wu SY, Chopra IJ, et al. Long term treatment of Graves' hyperthyroidism with sodium ipodate. J Clin Endocrinol Metab. 1985;61: 723-727
10. Clark RE, Shipley RA. Thyroidal uptake of I131 after iopanoic acid (telepaque) in 74 subjects. J Clin Endocrinol Metab. 1957;17: 1008-1010
11. Larsen PR, Dick TE, Markovitz BP, Kaplan MM, Gard TG. Inhibition of intrapituitary thyroxine to 3.5.3'-Triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats. J Clin Invest. 1979;64: 117-128
12. Kaplan MM, Yaskoski KA. Phenolic and tyrosyl ring deiodination of iodothyronines in rat brain homogenates. J Clin Invest. 1980;66: 551-562
13. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest. 2005;115: 2524-2533
14. Laurberg P, Vestergaard H, Nielsen S, et al. Sources of circulating 3, 5, 3'-Triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab. 2007;92: 2149-2156
15. Krogh C. Iopanoic Acid (Telepague, Sanofi Winthrop). Compendium of pharmaceuticals and specialties. 29th ed. Ottawa: Canadian Pharmaceutical Association, 1994: 1293
16. Felicetta JV, Green WL, Huber-Smith MJ. Effects of cholecystographic agents and sulfobromophthalein on binding of thyroid hormones to serum proteins. J Clin Endocrinol Metab. 1983;57: 207-212
17. Felicetta JV, Green WL, Nelp WB. Inhibition of hepatic binding of thyroxine by cholecystographic agents. J Clin Invest. 1980;65: 1032-1040
18. Laurberg P. Multisite inhibition by ipodate of iodothyronine secretion from perfused dog thyroid lobes. Endocrinology. 1985;117: 1639-1644
19. Cheron RG, Kaplan MM, Larsen PR. Physiological and pharmacological influences on thyroxine to 3, 5, 3'-Triiodothyronine conversion and nuclear 3, 5, 3'-Triiodothyronine binding in rat anterior pituitary. J Clin Invest. 1979;64: 1402-1414
20. Suzuki H, Kadena N, Takeuchi K, Nakagawa S. Effects of three-day oral cholecystography on serum iodothyronines and TSH concentrations: comparison of the effects among some cholecystographic agents and the effects of iopanoic acid on the pituitary-Thyroid axis. Acta Endocrinol (Copenh). 1979;92: 477-488
21. Karpman BA, Rapoport B, Filetti S, Fisher DA. Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate. J Clin Endocrinol Metab. 1987; 64: 119-123
22. Joshi R, Kulin HE. Treatment of neonatal Graves' disease with sodium ipodate. A case report. Clin Pediatr (Phila). 1993;32: 181-184
23. Transue D, Chan J, Kaplan M. Management of neonatal Graves disease with iopanoic acid. J Pediatr. 1992;121: 472-474
24. Earles SM, Gerrits PM, Transue DJ. Iopanoic acid in the management of neonatal Graves' disease. J Perinatol. 2004;24: 105-108
25. Wang YS, Tsou CT, Lin WH, Hershman JM. Long term treatment of Graves' disease with iopanoic acid (Telepaque). J Clin Endocrinol Metab. 1987;65: 679-682
26. Sharp B, Reed AW, Tamagra EI, Geffner DL, Hershman JM. Treatment of hyperthyroidism with sodium ipodate (oragrafin) in addition to propylthiouracil and propranolol. J Clin Endocrinol Metab. 1981;53: 622-625
27. Roti E, Robuschi G, Gardini E, et al. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf). 1988;28: 305-314.
28. Noguchi K, Suzuki H, Nakahata M, Kurosawa S, Nakagawa S. Prolonged treatment of hyperthyroidism with sodium tyropanoate, an oral cholecystographic agent: a re-evaluation of its clinical utility. Clin Endocrinol (Oxf). 1986;25: 293-301
29. Wu SY, Shyh TP, Chopra IJ, Solomon DH, Huang HW, Chu PC. Comparison sodium ipodate (oragrafin) and propylthiouracil in early treatment of hyperthyroidism. J Clin Endocrinol Metab. 1982;54: 630-634
30. Roti E, Robuschi G, Manfredi A, et al. Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves' disease. Clin Endocrinol (Oxf). 1985;22: 489-496
31. Robuschi G, Manfredi A, Salvi M, et al. Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease. J Endocrinol Invest. 1986;9: 287-291
32. Martino E, Balzano S, Bartalena L, et al. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. J Endocrinol Invest. 1991;14: 847-851
33. Roti E, Gardini E, Minelli R, Bianconi L, Braverman LE. Sodium ipodate and methimazole in the long-Term treatment of hyperthyroid Graves' disease. Metabolism. 1993;42: 403-408
34. Arteaga E, Lopez JM, Rodriguez JA, Michaud P, Lopez G. Effect of the combination of dexamethasone and sodium ipodate on serum thyroid hormones in Graves' disease. Clin Endocrinol (Oxf). 1983;19: 619-627
35. Pandey CK, Raza M, Dhiraaj S, Agarwal A, Singh PK. Rapid preparation of severe uncontrolled thyrotoxicosis due to Graves' disease with Iopanoic acid-A case report. Can J Anaesth. 2004;51(1): 38-40
36. Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves' disease. J Clin Endocrinol Metab. 2004;89(5): 2142-2144
37. Tomaski SM, Mahoney EM, Burgess LP, Raines KB, Bornemann M. Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism. Laryngoscope. 1997;107(8): 1066-1070
38. Bayot MR, Chopra IJ. Coexistence of struma ovarii and Graves' disease. Thyroid. 1995;5(6): 469-471
39. Berghout A, Wiersinga WM, Brummelkamp WH. Sodium ipodate in the preparation of Graves' hyperthyroid patients for thyroidectomy. Horm Res. 1989;31(5-6): 256-260
40. Chopra IJ, Baber K. Use of oral cholecystographic agents in the treatment of amiodarone-induced hyperthyroidism. J Clin Endocrinol Metab. 2001;86(10): 4707-4710
41. Bogazzi F, Bartalena L, Cosci C, et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab. 2003;88(5): 1999-2002
42. Bogazzi F, Aghini-Lombardi F, Cosci C, et al. Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. J Endocrinol Invest. 2002; 25(2): 176-180
43. Bogazzi F, Miccoli P, Berti P, et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. Surgery. 2002;132(6): 1114-1117; discussion 1118
44. Burman KD. Hyperthyroidism. In: Becker KL, Bilezikian JP, Bremner WJ, Hung W, eds. Principles and practice of endocrinology and metabolism. 2nd ed. Philadelphia: J.B. Lipincott Company, 1995: 367-385
45. de Luis DA, Abad L, Aller R, Gonzalez-Sagrado M, Duenas A. [Levothyroxine poisoning: clinical manifestations and therapeutic management]. An Med Interna. 2004; 21: 39-41
46. Brown RS, Cohen JH, 3rd, Braverman LE. Successful treatment of massive acute thyroid hormone poisoning with iopanoic acid. J Pediatr. 1998;132: 903-905
47. Redahan C, Karski JM. Thyrotoxicosis factitia in a postaortocoronary bypass patient. Can J Anaesth. 1994;41: 969-972
48. Kamel N, Uysal AR, Kologlu S, Erdogan G, Senel M, Polat H. Sodium ipodate in the treatment of toxic diffuse goiter. Short-Term and long-Term effects on thyrotoxicosis. Endocrinologie. 1988;26: 99-105
49. Gallagher AE, Panciera DL. Efficacy of iopanoic acid for treatment of spontaneous hyperthyroidism in cats. J Feline Med Surg. 2011;13: 441-447
50. Chopra IJ, van Herle AJ, Korenman SG, Viosca S, Younai S. Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis. J Clin Endocrinol Metab. 1995;80: 2178-2180
51. Martinez DS, Chopra IJ. Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis. Panminerva Med. 2003;45: 53-57
52. Dhillon KS, Cohan P, Kelly DF, Darwin CH, Iyer KV, Chopra IJ. Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid. J Clin Endocrinol Metab. 2004;89: 708-711
53. Luewan S, Chakkabut P, Tongsong T. Outcomes of pregnancy complicated with hyperthyroidism: a cohort study. Arch Gynecol Obstet. 2011;283: 243-247
54. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97: 2543-2565
55. Bahn RS, Burch HS, Cooper DS, et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009;19: 673-674.
56. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol. 1997; 79: 1436-1438
57. Rubin PC. Current concepts: beta-blockers in pregnancy. N Engl J Med. 1981;305: 1323-1326
58. Briggs GG FR, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 3rd ed. Baltimore: Williams & Wilkins, 1990
59. Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf). 1991;35: 439-442
60. Whitehouse WM, Martin O. A comparative clinical study of priodax and telepague, including 1, 000 examinations. Radiology. 1953;60: 215-221
61. Daymond TJ. Cholecystography and renal failure. Lancet. 1971;2: 549-550
62. Mudge GH. Cholecystography and renal failure. Lancet. 1971;2: 872
63. Canales CO, Smith GH, Robinson JC, Remmers AR, Jr., Sarles HE. Brief recordings. Acute renal failure after the administration of iopanoic acid as a cholecystographic agent. N Engl J Med. 1969;281: 89-91
64. Hysell JK, Hysell JW, Gray JM. Thrombocytopenic purpura following iopanoic acid ingestion. JAMA. 1977;237: 361-362
65. Bishopric GA. Athrombocytosis following oral cholecystography. JAMA. 1964;189: 771-772
66. Insausti CL, Lechin F, van der Dijs B. Severe thrombocytopenia following oral cholecystography with iocetamic acid. Am J Hematol. 1983;14: 285-288
67. Bal CS, Kumar A, Chandra P. Effect of iopanoic acid on radioiodine therapy of hyperthyroidism: long-Term outcome of a randomized controlled trial. J Clin Endocrinol Metab. 2005;90: 6536-6540
68. Bal C, Nair N. The therapeutic efficacy of oral cholecystographic agent (iopanoic acid) in the management of hyperthyroidism. J Nucl Med. 1990;31: 1180-1182
69. Shen DC, Wu SY, Chopra IJ, Shian LR, Florsheim W, Solomon DH. Further studies on the long-Term treatment of Graves' hyperthyroidism with ipodate: assessment of a minimal effective dose. Thyroid. 1991;1: 143-146
70. Wu SY, Chopra IJ, Solomon DH, Johnson DE. The effect of repeated administration of ipodate (Oragrafin) in hyperthyroidism. J Clin Endocrinol Metab. 1978;47: 1358-1362
71. Caldwell G, Errington M, Toft AD. Resistant hyperthyroidism induced by sodium iopodate used as treatment for Graves' disease. Acta Endocrinol (Copenh). 1989;120: 215-216
72. Ramos-Dias JC, Lengyel AM. Iopanoic acid-induced decrease of circulating T3 causes a significant increase in GH responsiveness to GH releasing hormone in thyrotoxic patients. Clin Endocrinol (Oxf). 1999;51: 461-467
73. Lizcano F, Salvador J. Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-Adrenal axis. Clin Exp Pharmacol Physiol. 2008;35: 1085-1090